scholarly journals Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) In Type 2 Diabetes Mellitus: A Systematic Review

2021 ◽  
Author(s):  
Tri Juli Edi Tarigan ◽  
Hadyanto Caputra ◽  
Irsan Hasan ◽  
Hamzah Shatri
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Intestinal Bacterial Overgrowth ◽  
Type 2 Dm ◽  
Small Intestinal ◽  
Diabetes Patients

Abstract Purpose: Gastrointestinal symptoms affect 50-70% of diabetic patients, resulting in a microbiota composition imbalance. Autonomic neuropathy is irreversible, resulting in diabetic enteropathy and sometimes even small intestine bacterial overgrowth (SIBO). SIBO can result in bile acid deconjugation, diarrhea, steatorrhea, vitamin and micronutrient malabsorption, weight loss, mucosal injury, bacterial translocation, and worsened intestinal motility. Carbohydrate malabsorption is related to the pathogenesis of diabetic macrovascular complications. The goal of this study is to find out how prevalent SIBO is in type 2 diabetes patients. Methods: "Small intestinal bacterial overgrowth," "small bowel bacterial overgrowth," “SIBO,” "type 2 diabetes mellitus," and "type 2 DM," are the keywords used. We searched Proquest, CINAHL, SCOPUS, ScienceDirect, PubMed/MEDLINE, and manual searches through world diabetes associations such as ADA, EASD, EFSD, IDF, FASEB, and PERKENI using the keywords. We use the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for bias risk assessment, and for data analysis, we use STATA 16. Results: Six articles covered 1072 type 2 diabetes patients in clinics and hospitals. With a minimum score of 7.42% and a maximum value of 53.85%, 95% CI 9.97-38.86, and an I2 of 97.17%, the pooled prevalence was 24.39% SD 15.31. HbA1c levels were higher (p=0.02) in type 2 DM patients with SIBO, and blood insulin levels were lower (p=0.001) in type 2 DM patients with SIBO. Each study was pretty varied, and there was evidence of publication bias. Assessment of findings based on GRADE is moderate. Conclusion: According to this study, SIBO is present in 24.39% of type 2 diabetes patients. SIBO conditions exacerbate the morbidity of patients with type 2 diabetes, as indicated by lower insulin levels and a higher HbA1c. In type 2 diabetes patients, a hydrogen breath test (HBT) is recommended to be performed regularly, especially in those who have had DM for more than 5 years.

scholarly journals THE INFLUENCE OF BACTERIAL OVERGROWTH SYNDROME ON THE EFFECTIVENESS OF ANTI-HELICOBACTER THERAPY IN PATIENTS WITH CHRONIC GASTRITIS AND TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 19 (1) ◽  
pp. 38-42
Author(s):  
T.O. Radionova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chronic Gastritis ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Overgrowth Syndrome ◽  
Intestinal Bacterial Overgrowth ◽  
Small Intestinal

Diabetic neuropathy often results in dysmotility of the gastrointestinal tract that induces further changes in its microbiotic spectrum. This can influence the course of concomitant diseases not related to diabetes mellitus and determine the effectiveness of their treatment. Aim: to investigate the effectiveness of anti-Helicobacter therapy in patients with chronic gastritis and concomitant type 2 diabetes, considering small intestinal bacterial overgrowth syndrome. Materials and methods: 64 patients with chronic Helicobacter pylori-positive gastritis were examined, 34 out of them had type 2 diabetes mellitus. Pantoprazole 40 mg, clarithromycin 500 mg, amoxicillin 1000 mg bid were prescribed to all the patients for 10 days. Before the treatment, on the 14th and 28th days of the therapy, a hydrogen breath test with lactulose to reveal small intestinal bacterial overgrowth, gastrointestinal symptoms monitoring, and re-determining Helicobacter pylori focal antigen on 28th day were performed. Results: on the 14th day of the treatment a decrease in the pain syndrome (n=28, 93% vs. n=10, 33%; p> 0.05), postprandial fullness (n=14, 47% vs. n = 4, 13% p>0.05) and nausea (n=13, 43% vs. n=4, 13% p>0.05) was observed among the non-diabetic patients with chronic gastritis. No statistical significance regarding abdominal pain regressing in patients with type 2 diabetes mellitus was found (n=16, 47% vs. n=9, 26%), postprandial fullness did not change noticeably (n=27, 79% vs. n=26, 76%), while the frequency of nausea increased (n=14, 41% vs. n=18, 53%). The incidence of small intestinal bacterial overgrowth significantly increased compared with the data before the therapy (n=16, 47% vs. n=27, 79%; p>0.05) and with non-diabetic patients (n = 15, 50% vs. n = 27,79%; p> 0.05). The effectiveness of H. pylori therapy was higher among patients without diabetes mellitus (77% vs. 65%). Conclusions: it has been found out anti-Helicobacter therapy is less effective in the patients with chronic gastritis and concomitant type 2 diabetes mellitus that is accompanied by the enhancement of bacterial overgrowth syndrome and associated with worse clinical dynamics compared to patients without carbohydrate metabolism disorders.

scholarly journals DO H. PYLORI STATUS AND SMALL INTESTINAL BACTERIAL OVERGROWTH DETERMINE THE CLINICAL COURSE OF CHRONIC ACTIVE GASTRITIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS?

2020 ◽  
Vol 73 (6) ◽  
pp. 1223-1228
Author(s):  
Tetiana O. Radionova ◽  
Igor M. Skrypnyk ◽  
Ganna S. Maslova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Epigastric Pain ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Postprandial Fullness ◽  
Chronic Active Gastritis ◽  
Intestinal Bacterial Overgrowth ◽  
Small Intestinal

The aim: To define clinical peculiarities of chronic active gastritis in patients with type 2 diabetes mellitus (T2DM) considering Helicobacter pylori (HP) status and small intestinal bacterial overgrowth (SIBO). Materials and methods: 172 patients with chronic active gastritis were enrolled in the study, 92 out of them had concomitant T2DM. Symptoms were collected with the questionnaire, HP infection was diagnosed with stool antigen test, SIBO was assessed with glucose hydrogen breath test. Results: 87.5% (n=70) patients with chronic gastritis without DM had epigastric pain, however those with T2DM reported pain only in 41.3% (n=38) cases. Other symptoms included: nausea, bloating, early satiety, postprandial fullness, heartburn, belching and vomiting. HP infection in patients with chronic gastritis and concomitant T2DM is significantly associated with symptoms of epigastric pain (OR=2.78, 95%CI 0.92-8.41), bloating (OR=3.92, 95%CI 1.40-10.99), nausea (OR=2.32, 95%CI 0.85-0.6.30), postprandial fullness (OR=1.45, 95%CI 0.54-3.87) and belching (OR=1.01, 95%CI 0.32-3.16), whereas SIBO – with bloating (OR=8.82, 95%CI 2.88-27.01), nausea (OR=5.15, 95%CI 1.88-14.10) and belching (OR=2.53, 95%CI 0.67-9.52). Conclusions: Patients with T2DM and chronic active gastritis report epigastric pain significantly less than non-diabetics. HP infection probably plays a prominent role in development of epigastric pain in patients with T2DM. Additionally, HP is linked to SIBO, which may lead to bloating, belching and nausea onset.

scholarly journals The Prevalence of Small Intestinal Bacterial Overgrowth in Diabetes Mellitus: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Xiao-Qing Li ◽  
Xin Feng ◽  
Zheng Jiang
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Breath Test ◽  
Meta Analysis ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Intestinal Bacterial Overgrowth ◽  
Pooled Prevalence ◽  
Small Intestinal ◽  
Diabetes Patients

Abstract Objective: The reported prevalence of small intestinal bacterial overgrowth (SIBO) among patients with diabetes mellitus (DM) is highly variable. We conducted this systematic review and meta-analysis to estimate the prevalence of SIBO in DM.Methods: A comprehensive literature search of the PubMed, Cochrane Library and Embase databases from inception to December 2020 was conducted for studies correlating SIBO with DM. Studies were screened, and relevant data were extracted and analysed. The pooled prevalence of SIBO among DM patients and the odds ratio (OR) of SIBO among DM patients compared with controls were calculated. Publication bias was assessed using Egger’s test and funnel plots.Results: Fourteen studies including 1417 diabetes patients and 649 controls met the inclusion criteria. The pooled prevalence of SIBO in DM was 29% (95% CI 20–39%). The OR of SIBO in diabetes patients was 2.91 (95% CI 0.82–10.32, p=0.1) compared with controls. Subgroup analyses showed that the prevalence of SIBO in DM was higher in studies using jejunal aspirate culture (JAC) for diagnosis (39%, 95% CI 12–66%) than in those that used the lactulose breath test (LBT) (31%, 95% CI 18–43%) or glucose breath test (GBT) (29%, 95% CI 14–43%). The prevalence of SIBO in DM was higher in studies conducted in Western countries (35%, 95% CI 21–49%) than in those conducted in Eastern countries (24%, 95% CI 14–34%), and the prevalence of SIBO in type 1 DM (25%, 95% CI 14%–36%) was not significantly different from that in type 2 DM (30%, 95% CI 13%–47%).Conclusion: Twenty-nine percent of diabetes patients tested positive for SIBO and had a significantly higher risk than the controls. The prevalence of SIBO in DM varied according to the diagnostic test performed and geographic area. DM could be a predisposing factor for the development of SIBO, especially among patients diagnosed by JAC or those in Western populations.

scholarly journals CORRELATION BETWEEN THE ROLE OF NURSE AS EDUCATOR AND SELF CARE BEHAVIOUR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INTERNAL MEDICINE UNIT OF BINA SEHAT HOSPITAL JEMBER

2017 ◽  
Vol 2 (1) ◽  
pp. 61
Author(s):  
Rima Ulfa Fahra ◽  
Nur Widayati ◽  
Jon Hafan Sutawardana
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Self Care ◽  
P Value ◽  
Type 2 Dm ◽  
Nurse Role ◽  
Diabetes Patients

Diabetes mellitus (DM) is a chronic disease that requires continuous self-care. Education by nurses can support self-care behavior of patients with type 2 DM. Good knowledge affects self-care of type 2 diabetes patients so that metabolic control can be achieved. This study aimed to identify the correlation between the role of nurse as educator and self-care behaviour in patients with type 2 diabetes mellitus. This research applied a descriptive analytic design with cross sectional approach. A total of 63 respondents were enrolled in this study by using consecutive sampling technique. Data collection was conducted by administering questionnaires of nurse role as educator and Summary of Diabetes Self Care Activities (SDSCA). Data were analyzed by using Spearman correlation test with significance level of 0.05. The result showed that the mean value of nurse role and self-care behaviour was 59.84 and 3.79 respectively. The p value was 0.000 (p<0.05) with the correlation coefficient (r) of 0.851. It indicates that there was a significant correlation between nurse role as educator and self-care behaviour in patients with type 2 DM. The correlation was strong and positive which means the better the nurse's role as educator the better the patient's self-care behaviour. The education gained by the patients can affect the motivation to perform self-care behaviour. This study suggests the importance of nurse role in providing education in type 2 diabetes patients to optimize self-care behaviour.

Small Intestinal Bacterial Overgrowth Is Associated with Non- Alcoholic Fatty Liver Disease

2016 ◽  
Vol 25 (2) ◽  
pp. 159-165 ◽  
Author(s):  
Andrea Fialho ◽  
Andre Fialho ◽  
Prashanthi Thota ◽  
Arthur J. McCullough ◽  
Bo Shen
Keyword(s):  
Risk Factors ◽  
Fatty Liver Disease ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Study Group ◽  
Alcoholic Fatty Liver ◽  
Intestinal Bacterial Overgrowth ◽  
Small Intestinal ◽  
Alcoholic Fatty Liver Disease

Background: Changes in gut bacteria play a role in type 2 diabetes mellitus (DM) and hepatic steatosis. There is a lack of studies evaluating the frequency and risk factors for non-alcoholic fatty liver disease (NAFLD) in patients tested for small intestinal bacterial overgrowth (SIBO). Aim: To evaluate the frequency of NAFLD and associated risk factors in patients tested for SIBO. Methods: In this case-control study, 372 eligible patients submitted to glucose hydrogen/methane breath test for SIBO who also had an abdominal imaging study were included. Patients were divided into SIBO-positive and SIBO-negative groups. Clinical, demographic and laboratory variables were evaluated in addition to the presence of NAFLD on abdominal imaging. Results: Of the 372 eligible patients, 141 (37.9%) were tested positive for SIBO (study group) and 231 (62.1%) were negative for it (control group). NAFLD occurred in 45.4% (64/141) of the study group compared to 17.3% (40/231) of the control group (p<0.001). Patients in the study group were found to have higher rates of elevated aspartate aminotransferase (AST) (20.6% vs. 11.3%; p=0.034) and alanine aminotransferase (ALT) levels (56.0% vs. 40.7%; p= 0.039), type 2 diabetes (23.4% vs. 13.9%; p=0.041), hypertension (54.6% vs. 40.3%; p=0.046) and metabolic syndrome (78.0% vs. 60.2%; p=0.020). In the multivariate analysis, SIBO (odds ratio [OR]: 1.95; 95% confidence interval [CI]: 1.14-3.31; p=0.014), type 2 DM (OR: 3.04; 95%CI: 1.57-5.90; p=0.001) and obesity (OR: 3.58; 95%CI: 1.70-7.54; p=0.001) remained associated with NAFLD.Conclusion: Patients with SIBO have an increased risk for hepatic steatosis and may benefit from aggressive control of the risk factors for NAFLD including metabolic syndrome. Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CTE: computed tomography enterography; DM: diabetes mellitus; ETOH: ethanol; IL: interleukin; LPS: lipopolysaccharide; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; PPI: proton pump inhibitor; SIBO: small intestinal bacterial overgrowth; TLR-4: toll-like receptor 4; TMAO: trimethylamine-N-oxide (TMAO); TNF-α: tumor necrosis factor alpha.

scholarly journals Efektivitas Kurma (Phoenix dactylifera) dalam menurunkan kadar HbA1c pada pasien diabetes mellitus tipe 2: Laporan Kasus Berbasis Bukti

2020 ◽  
Vol 3 (1) ◽  
pp. 31-45
Author(s):  
Muhammad Sobri Maulana ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hba1c Level ◽  
Phoenix Dactylifera ◽  
Herbal Remedies ◽  
Cochrane Library ◽  
Time Treatment ◽  
Type 2 Dm

Type 2 Diabetes Mellitus or Type 2 DM is a metabolic disease that can cause severe complications so that adequate management which one of the targets is lowering HbA1c level is needed. Up to this time, treatment for Type 2 DM including antihiperglycemic and injection. Herbal remedies as well as dates (Phoenix datcylifera) has been limited even though it has well-known antihyperglycemic effect. To investigate the effectivity of Dates (Phoenix dactylifera) in lowering HbA1c level among Type 2 Diabetes Mellitus patients. Literature searching was conducted on four online databases which are PubMed, Scopus, EBSCO, and Cochrane Library based on inclusion and exclusion criterias. Based on the results of critical studies, seven studies have shown that there is effectiveness in the administration of Dates (Phoenix dactylifera) in patients with type 2 diabetes mellitus on Lowering HbA1c levels and restricition of date diet needed for type 2 diabetes mellitus patients in 3 dates per day that are statistically significant for lowering HbA1c level with value of NNT is 1. Administration of Dates (Phoenix dactylifera) can be used as an adjuvant therapy on Type 2 Diabetes mellitus patients

scholarly journals Correlation Between Lipid Profile with Type 2 Diabetes Mellitus Progression

2020 ◽  
Vol 8 (2) ◽  
pp. 66-72
Author(s):  
Angiesta Pinakesty ◽  
Restu Noor Azizah
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Cholesterol Levels ◽  
Type 2 Dm ◽  
Hba1c Levels

Introduction: Diabetes mellitus (DM) is a non-communicable disease that has increased from year to year. Type 2 diabetes mellitus is not caused by lack of insulin secretion, but is caused by the failure of the body's cells to respond to the hormone insulin (insulin resistance). Insulin resistance was found to be a major contributor to atherogenic dyslipidemia. Dyslipidemia in DM risks 2 to 4 times higher than non-DM. Although dyslipidemia has a great risk for people with type 2 diabetes mellitus, this conventional risk factor only explains a portion (25%) of excess cardiovascular risk in type 2 DM. Discussion: In uncontrolled type 2 DM patients, LDL oxidation occurs faster which results from an increase in chronic blood glucose levels. Glycemic control as a determinant of DM progressivity is determined through HbA1c examination. HbA1c levels are associated with blood triglyceride levels. Meanwhile, triglyceride levels are associated with total cholesterol and HDL cholesterol levels. HbA1c levels are also associated with LDL cholesterol levels. Conclusion: There is a relationship between lipid profile and the progression of type 2 diabetes mellitus.   Keywords: type 2 diabetes mellitus, dyslipidemia, HbA1c, glycemic control, lipid profile

Sign in / Sign up

Export Citation Format

Share Document